PCSK9 and myocardial infarction: In the SPIRE outcomes trials of PCSK9-inhibitor therapy which were prematurely terminated (and so involved smaller numbers of events), the rate of non-fatal stroke was also reduced by at least as much as for non-fatal myocardial infarction.16